HIV-positive patients with virological suppression did not have different rates of aging-relating cognitive decline compared with HIV-negative patients.
HIV-positive individuals with higher alcohol levels performed worse on several cognitive tests, however alcohol was not the primary factor.
HIV patients had reduced brain volume and poorer cognitive performance.
Patients with HIV treated with cART have lower neuropsychological test scores than controls, but no significant neuropsychological decline over time.
Evaluating the risk factors of neurocognitive decline in HIV.
Effective cognitive screening instruments are needed in order to assess and manage milder forms of HIV-associated neurocognitive disorders.
Early detection and robust treatment are critical to limiting deficits in achieving developmental milestones in HIV-infected infants.
The results indicate HERV-K activation as a potential mechanism for HIV-associated ALS.
For the most part, symptoms tend to subside after treatment initiation.
Until now, it was thought that HIV-related inflammation protected the brain from amyloid deposition.
Paroxetine use improved cognitive impairment and reduced inflammation in HIV patients.
The URMC-099 compound combined with antiretroviral therapy significantly reduced HIV levels.
CSF cultures were negative despite worsening meningitis infection.
Researchers are now testing whether antiretroviral drugs used to treat HIV/AIDS are effective in ALS patients.
The findings may have implications for the development of future vaccines.
The new treatment would need to be combined with other HIV drugs or antibodies.
The brain can harbor active HIV even after seemingly successful antiretroviral treatment.
Some coping strategies like substance abuse may have negative affects on overall health.
Neurology Advisor Articles
- Higher Levels of Cholesterol May Protect Men From Parkinson Disease
- Early Clinical Traits of Multiple Sclerosis Prodrome Identified
- Chronic Pain May Be Contributor to Suicide
- FDA Approves Tiglutik for the Treatment of Amyotrophic Lateral Sclerosis
- Ajovy Injection Approved for Migraine Prevention in Adults
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Brivaracetam Effective for Reducing Seizures in Patients with Epileptic Encephalopathies
- Familial Hemiplegic Migraine Attacks May Be Associated With Cortical Swelling
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- Fremanezumab May Have Long-Term Efficacy as a Prophylactic for Chronic Migraine
- Propofol May Decrease Delay in Neurocognitive Recovery